Glutathione-S-transferase mu as a measure of drug resistance
US5204241A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Oct 22, 1990 |
| Grant date | Apr 20, 1993 |
| Priority date | — |
| Expiry date | Oct 22, 2010 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
It has been discovered that by determining or measuring a person's glutathione-s-transferase (GST) mu activity one can determine or measure the individual's resistance to drugs, particularly to chemotherapeutic drugs. Approximately 50% of the human population exhibit substantially no GST mu activity, with the remaining 50% showing GST mu activity. This remaining 50% of the population accordingly, when treated with drugs, such as a chemotherapeutic drug for cancer therapy, show less effective response to the drug therapy than the other 50% of the population which have substantially no GST mu activity, since GST mu tends to deactivate drugs. Accordingly, a person having GST mu activity would exhibit drug resistance and would not benefit as much by or be as good a candidate for cancer chemotherapy as a person who has no GST mu activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.